SCHEMBL26270734

SCHEMBL26270734

CC(C)(C)OC(=O)NCC(=O)Nc1ccccc1Sc1ccc(F)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.55
▸ KMT2A Q03164 7/20 0.49
▸ LMNA P02545 6/20 0.49
▸ MEN1 O00255 5/20 0.49
▸ NPSR1 Q6W5P4 3/20 0.49
▸ L3MBTL1 Q9Y468 8/20 0.49
▸ ALDH1A1 P00352 6/20 0.49
▸ GLA P06280 1/20 0.49
▸ BLM P54132 2/20 0.46
▸ NOD2 Q9HC29 1/20 0.46
▸ HPGD P15428 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ TDP1 Q9NUW8 2/20 0.44
▸ POLB P06746 1/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26270721 0.91 KMT2A (0.57) MAPK1KMT2ALMNAMEN1NPSR1
SCHEMBL26270731 0.88 MAPK1 (0.47) MAPK1KMT2ALMNAMEN1NPSR1
SCHEMBL30567229 0.86 KMT2A (0.42) MAPK1KMT2ALMNAMEN1L3MBTL1
SCHEMBL26270728 0.86 KMT2A (0.42) MAPK1KMT2ALMNAMEN1L3MBTL1
SCHEMBL25385007 0.82 MAPK1 (0.67) MAPK1KMT2ALMNAMEN1NPSR1
SCHEMBL26270737 0.81 ALDH1A1 (0.51) KMT2ALMNAMEN1L3MBTL1ALDH1A1
SCHEMBL5864434 0.77 ALDH1A1 (0.53) MAPK1KMT2AMEN1L3MBTL1ALDH1A1
SCHEMBL12822326 0.76 POLB (0.66) KMT2ALMNAMEN1L3MBTL1ALDH1A1
SCHEMBL29193980 0.76 LMNA (0.45) KMT2ALMNAALDH1A1POLBHTT
SCHEMBL25385549 0.76 MAPK1 (0.71) MAPK1KMT2ALMNAMEN1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171404-A1 PCNA INHIBITORS AND USES THEREOF UNITED STATES GOVERNMENT 2025-05-29 — — US disclosed
EP-4490142-A2 PCNA INHIBITORS AND USES THEREOF City of Hope (US) 2025-01-15 — — EP disclosed
WO-2023172880-A2 PCNA INHIBITORS AND USES THEREOF CITY OF HOPE (US) 2023-09-14 — — WO disclosed
WO-2023172880-A2 PCNA INHIBITORS AND USES THEREOF CITY OF HOPE (US) 2023-09-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171404-A1 PCNA INHIBITORS AND USES THEREOF PCNA, MKI67, PCLAF MAPK1 1681/4885KMT2A 1014/4885LMNA 1607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback